Hack #9| Entrepreneurship is Boundaryless

#9 Hack of The Week emphasizes the importance of collaboration, global networking, and embracing the entrepreneurial ecosystem to foster innovation and resilience. It highlights real-world examples, such as the rental umbrella service in Tokyo and the airport operations industry’s successful recovery after the COVID-19 pandemic.

Tech Tuesday: CordaRoy’s

Byron Young, founder and CEO of CordaRoy’s, discusses the origin of bean bag beds and the company’s success on WCJB TV20’s Tech Tuesday. CordaRoy’s, based in Gainesville since 1998, started as bean bag chairs and evolved into beds when the founder improvised for extra guests. The idea was patented, and the company is now renowned for its bean bag beds, using recycled foam and offering a lifetime warranty.

University of Florida and Synhelion To Scale Up Solar Hydrogen Energy Solution

Synhelion and its partner, University of Florida, announced today that their joint project has been awarded US$ 2.7 million from the U.S. Department of Energy Solar Energy Technologies Office (SETO). The project aims to accelerate the large-scale development and deployment of concentrating solar thermal power (CSP) technology to produce green hydrogen for industrial decarbonization and electric power generation and storage.

UF Health Shands Children’s Hospital Nationally Ranked in Four Specialties

University of Florida Health Shands Children’s Hospital’s diabetes and endocrinology program is now ranked among the nation’s top 10 by U.S. News & World Report. It is the highest ranking ever for the program, which is joined in the standings by three other UF Health pediatric medical specialties, according to the 2023-24 Best Children’s Hospital rankings.

Kate Therapeutics Debuts With $51 Million Series A To Develop Next-Generation Genetic Medicines To Treat Muscle and Heart Diseases

Kate Therapeutics Inc., a next-generation gene therapy company, has emerged from stealth mode after securing a $51 million Series A financing round. The funding was co-led by Westlake Village BioPartners and Versant Ventures, with participation from Osage University Partners and UF Innovate | Ventures. Additionally, the company has granted Astellas Pharma Inc. an exclusive worldwide license to develop, manufacture, and commercialize KT430 for the treatment of X-linked myotubular myopathy (XLMTM).